OIG - Office of Inspector General
01/06/2025 | Press release | Distributed by Public on 01/06/2025 17:42
Bothell Biopharmaceutical Company Pays $4 Million To Resolve Allegations It Relied On Falsified Academic Papers To Obtain Federal Grant
Bothell Biopharmaceutical Company Pays $4 Million To Resolve Allegations It Relied On Falsified Academic Papers To Obtain Federal Grant
CEO resigned after her doctoral work was found to have falsified and manipulated images
Seattle - A Bothell, Washington, pharmaceutical company will pay $4,068,698 to resolve allegations it used falsified academic research to obtain grants from the National Institute of Health (NIH), announced U.S. Attorney Tessa M. Gorman. The research studies in question were into age-related cognitive decline such as Alzheimer's. However, when the company applied for a federal grant, it failed to notify NIH of allegations that its former Chief Executive Officer (CEO) committed research misconduct when she falsified images from her doctoral dissertation. The allegations were called to the government's attention through a qui tam lawsuit. The relator will receive a portion of the payment for uncovering the fraud.
Action Details
- Date:January 6, 2025
- Agency:U.S. Attorney's Office, Western District of Washington
-
Enforcement Types:
- Criminal and Civil Actions
Share
OIG - Office of Inspector General published this content on January 06, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 06, 2025 at 23:42 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io